Table II.
Salient features of ongoing PrEP trials (from http://data.avac.org/OngoingPrEPTrials.aspx)
| Trial name | Phase | Start date | Locations | Sponsor/funder | Population | Intervention arms | Results expected |
|---|---|---|---|---|---|---|---|
| iPREX OLE | Open Label | June 2012 | Brazil, Ecuador, Peru, South Africa, Thailand, United States | NIAID | 1500 Men | Daily oral TDF-FTC | November 2013 |
| CDC 494 (TDF2 Follow-Up Open Label Extension) | Open Label | November 2012 | Botswana | Botswana Ministry of Health, CDC, Gilead | 1200 Women, Men | Daily oral TDF-FTC | November 2013 |
| CDC 4370 (Bangkok Tenofovir Study) | III, II | June 2005 | Thailand | CDC, Bangkok Metropolitan Administration (BMA) | 2400 Injecting drug users | Daily oral TDF-FTC | December 2012 |
| Partners PrEP | III | July 2008 | Kenya, Uganda | BMGF | 4700 Women, Men, Heterosexual, Serodiscordant | Daily oral TDF-FTC, Oral TDF | January 2013 |
| ANRS IPERGAY | III | January 2012 | Canada, France | ANRS | 1900 MSM | Intermittent oral TDF-FTC | December 2016 |
| HPTN 069/ACTG 5305 (NEXT-PrEP) | II | February 2012 | United States | ACTG, HPTN, NIAID | 400 Gay men and other men who have sex with men, Men | MVC 300 mg, MVC 300 mg + TDF 300 mg, MVC 300 mg + FTC 200 mg, TDF 300 mg + FTC 200 mg | January 2014 |
| HPTN 067 (ADAPT) | II | January 2011 | South Africa, Thailand | DIADS, Gilead, HPTN, NIMH | 360 Heterosexual women, MSM | Intermittent oral TDF-FTC | September 2012 |
| HPTN 066 | I | January 2011 | HPTN | 32 Women, Men | Different dosing schedules of TDF-FTC | October 2011 | |
| SSAT 040 (TMC278LA) | I | January 2011 | United Kingdom | St Stephen’s AIDS Trust | 66 Men, Women | TMC278 LA | February 2012 |
| MTN 003B | Other | November 2009 | Uganda, Zimbabwe | Gilead, MTN, NIAID | 518 Women | Daily oral TDF-FTC, Oral TDF | January 2013 |